48 search results for: asthma

Airway Hyperresponsiveness In <b>Asthma</b> Is Mainly Driven By  Components Of Type 2 Inflammation
Pulmonology
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation
interactivity

Examine underlying type 2 inflammation as a driver of airway hyperresponsiveness in patients with asthma.

View more
The Burden in Patients with CRSwNP and Coexisting <b>Asthma</b>
Pulmonology
The Burden in Patients with CRSwNP and Coexisting Asthma
expert video

This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

View more
Screen depicting a mucus plug in the airways
Pulmonology
A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma
videoanimation

Explore the role of type 2 inflammation in the production of mucus plugs in asthma and the effects these plugs can have on patients.

View more
ERS 2025 | Type 2 Severe <b>Asthma</b> "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes
Pulmonology
ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes
videoanimation

Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.

View more
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 <b>Asthma</b>
Pulmonology
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
expert video

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.

View more
ERS 2025 Enduring Video: Type 2 Severe <b>Asthma</b> “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes
On Demand
ERS 2025 Enduring Video: Type 2 Severe Asthma “Unplugged”: Reducing Mucus to Improve Long- Term Patient Outcomes

Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.

How Type 2 Inflammation Drives Eosinophils in <b>Asthma</b>
Pulmonology
How Type 2 Inflammation Drives Eosinophils in Asthma
videoanimation

Explore how type 2 inflammation drives the production of eosinophils in severe asthma.

View more
thumbnail
Congress
17
May
2026
Congress
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for <b>Asthma</b> Patients
Pulmonology
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients
Infographic

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.

View more
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe <b>Asthma</b>
Pulmonology
ERS 2026 | Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma
expert video

Join experts Frederik Trinkmann, Monica Kraft, and Arnaud Bourdin on an ADVENT educational symposium, “Distal Airways, Central Role? Clinical Insights Into Type 2 Severe Asthma."

View more
The Weight of Breath: The Impact of Pediatric <b>Asthma</b> on Patients and Caregivers
Pulmonology
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers
videoanimation

Learn about the multifaceted burden of uncontrolled pediatric asthma on patients and their caregivers.

View more
ADVENT at ATS 2026
On Demand
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​